Analyst Price Target is $1.50
▲ +737.99% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Histogen in the last 3 months. The average price target is $1.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 737.99% upside from the last price of $0.18.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Histogen.
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.